Daktari Diagnostics

Volatylix, Inc., based in Cambridge, MA, is committed to fostering innovation and entrepreneurship in the United States through its involvement in the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. These initiatives provide non-dilutive funding to small businesses and startups, enabling them to develop and commercialize their technological solutions while maintaining ownership of their equity and intellectual property. Every year, America's Seed Fund invests approximately $4 billion, supporting around 4,000 companies in their pursuit of scientific and technological advancements. With a strong focus on job creation and economic impact, the program has added over 65,000 jobs to the U.S. economy annually, highlighting its crucial role in driving innovation and addressing federal research and development needs. Generated from the website

Headquartered in Cambridge, Mass., Biogen Idec specializes in the field of biotechnology. Its core capabilities include drug discovery, research and development. The company s focus is the development of products related to oncology, neurology and immunology. Among the company s products are treatments for B-cell, non-Hodgkin s lymphomas; a treatment for relapsing forms of multiple sclerosis; and a treatment for psoriasis and psoriatic arthritis. In addition, the company has several licensed and dedicated bulk-manufacturing facilities engaged in protein manufacturing. James C. Mullen has been the chief executive officer of Biogen Indec for more than two years. He has been with the drug and biotechnology company for over 17 years. Mullen earned a BS degree from Rensselaer Polytech, and a MBA from Villanova. The company maintains research centers in Cambridge, Mass., and San Diego. Biogen Idec has additional offices in Canada, Australia, Japan and Europe, including international headquarters in Zug, Switzerland. The company currently employs approximately 3,400 people worldwide.

In operation since 1981, Genzyme Corporation is one of the leading biotechnology companies in the world. The company employs a staff of more than 12,000 people and manages over 85 locations in nearly 40 countries. It focuses on the areas of hematologic oncology, biosurgery, transplant, genetic diseases, and cardiometabolic and renal. Genzyme Corporation offers Fabrazyme, which is a solution for intravenous infusion. The company also provides Fabrazyme, Renagel, Renvela and Hectorol. It offers solutions for the medical and patient communities. In addition, Genzyme Corporation offers Synvisc, which is a viscosupplementation treatment for relieving knee pain associated with osteoarthritis. The company provides Sepra, which is a line of hyaluronic acid-based products.